Effect of concomitant use of enzyme-inducing antiepileptics on serum levels of digitoxin in a population;Serum-digitoksin ved samtidig bruk av antiepileptika i rutinebehandling

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 14, 1997, Pages 2032-2035

  Aass, Halfdan ^a   Johannessen, Svein I ^b   Osnes, Jan Bjørn ^c   Skomedal, Tor ^c   Stokke, Kjell Torgeir ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Statens Senter for Epilepsi   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d Furst Medisinsk Laboratorium   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIGITOXIN; LITHIUM; PHENOBARBITAL; PHENYTOIN;

ARTICLE; DRUG BLOOD LEVEL; ENZYME INDUCTION; HUMAN; MAJOR CLINICAL STUDY;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CARBAMAZEPINE; DIGITOXIN; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; PHENOBARBITAL; PHENYTOIN;

EID: 0030786512     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. London: Lea & Febiger, 1991.
2. Levy RH, Mattson RH, Meldrum BS, red. Antiepileptic drugs. 4. utg. New York: Raven Press, 1995.
3. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trend Pharmacol Sci 1992; 13: 434-9.
4. Brøsen K. Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord J Psychiatr 1993; 47 (suppl 30): 21-6.
5. Rang HP, Dale MM, Ritter JM, red. Pharmacology. London: Churchill Livingstone, 1995.
6. Tørisen HM, red. Felleskatalog over farmasøytiske spesialpreparater markedsført i Norge 1996/97. 38. utg. Oslo: Felleskatalogen A/S, 1996.
7. Vennerød AM, red. Norsk legemiddelhåndbok 1996-97 for helsepersonell. Oslo: Norsk legemiddelhåndbok I/S, 1996.
8. Skomedal T, Osnes J-B, Johannessen SI, Lund PK, Aass H. Terapikontroll ved hjelp av serumkonsentrasjonsmåling av medikamenter. Hvordan fordeler analysesvarene seg i en populasjon? Tidsskr Nor Lægeforen 1993; 113: 2242-6.
9. Rameis H. The importance of prospective planning of pharmacokinetic trials. Int J Clin Pharmacol Ther Toxicol 1992; 30: 528-9.
10. Eberhart DC, Gemzik B, Halvorsen MR, Parkinson A. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Molec Pharmacol 1991; 40: 859-7.
11. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J 1993; 6: 745-8.